Clinical Trial Update: 68Ga-FAPI PET/CT in Malignant Tumors [NA]

View source ↗

Summary

This clinical trial evaluates 68Ga-FAPI PET/CT imaging for detecting and characterizing malignant tumors and is currently recruiting at Zhongnan Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• 68Ga-FAPI PET/CT (68Ga-labeled FAPI PET imaging tracer)
• Fibroblast Activation Protein Inhibitor (FAPI) (Fibroblast Activation Protein Inhibitor)

Snippet

Sponsor: Zhongnan Hospital | Conditions: Fibroblast Activation Protein Inhibitor, PET/CT | NA | Status: RECRUITING